Ubiquigent Obtains Exclusive License for UbiSite Technology to Strengthen its Specialist Drug Discovery Services

Dundee, UK, 31 October 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology. UbiSite will form a new component in Ubiquigent’s DUB and ubiquitin-proteasome system (UPS) focused drug discovery platform, providing a fully supported ubiquitomics service to facilitate target identification, target validation, and compound mechanism of action.
More info >>